2 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, psychiatric disorderActive, not recruitingPhase 22026-08-03NCT07741526
Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Cerebral Amyloid Angiopathy, Familial, Cerebral Small Vessel Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemorrhage, Intracranial Hemorrhages, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, amyloidosis, brain disorder, cardiovascular disorder, central nervous system disorder, cerebral amyloid angiopathy, cerebral arterial disease, cerebrovascular disorder, cognitive disorder, dementia, hereditary amyloidosis, hereditary disease, inborn errors of metabolism, intracerebral hemorrhage, intracranial arterial disease, metabolic disease, nervous system disorder, proteostasis deficiencies, psychiatric disorder, vascular disorderActive, not recruitingPhase 22026-07-21NCT07716865